Choosing Between Two Frontline Regimens in DLBCL

Dr. Lunning discusses decision-making when both Pola-R-CHP and Tafa-Len-R-CHOP are options. He begins with FISH testing: for confirmed high-grade B-cell lymphoma with MYC and BCL-2 rearrangements (double-hit), dose-adjusted R-EPOCH remains his preference outside clinical trials, as these patients tend toward GCB subtype and higher IPI. For non-double-hit patients, frontMIND's arrival opens the door to Tafa-Len-R-CHOP particularly for GCB-subtype higher-risk patients.

He raises important operational differences between the two regimens: Pola-R-CHP follows a standard day-1/day-21 blood monitoring rhythm, whereas frontMIND required weekly complete blood counts, likely driven by the lenalidomide component. He questions whether real-world cytopenia rates will be as high as trial rates, suggesting weekly monitoring may have amplified detection of subclinical cytopenias rather than reflecting true drug toxicity differences.

When asked whether R-CHOP still has a place, Dr. Lunning argues its days are numbered for IPI 2+ disease. He preserves it for early-stage disease meeting FLYER criteria (limited stage, low IPI, 4 cycles of R-CHOP), or combined modality approaches with abbreviated chemotherapy plus radiation. He frames 2026 as the era that moves beyond R-CHOP, drawing a historical arc from 8 cycles to 6 cycles of CHOP-based therapy, anticipating further duration refinement ahead.